New molecular entity (NME)

(RG6234)

Hematology

Phase I

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

NCT04557150